Entera Bio Ltd. (NASDAQ: ENTX) Q4 2020 earnings call dated Mar. 18, 2021 Corporate Participants: Jonathan Lieber -- Chief Financial Officer, U.S.
Entera Bio Ltd. (ENTX) Q4 2020 Earnings Call Transcript
Categories
Biotechnology
Avid Bioservices, Inc. (CDMO) Q3 2021 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ: CDMO) Q3 2021 earnings call dated Mar. 08, 2021 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President and Chief
Moderna (MRNA) to increase vaccine supply capacity and accelerate pipeline investments
Shares of Moderna Inc. (NASDAQ: MRNA) were up 6% in morning trade on Thursday after the company reported its fourth quarter and
Sage Therapeutics Inc. (SAGE) Q4 2020 Earnings Call Transcript
Sage Therapeutics Inc. (NASDAQ: SAGE) Q4 2020 earnings call dated Feb. 24, 2021 Corporate Participants: Jeff Boyle -- Vice President, Head of Investor Relations
Jazz Pharmaceuticals PLC (JAZZ) Q4 2020 Earnings Call Transcript
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) Q4 2020 earnings call dated Feb. 23, 2021 Corporate Participants: Andrea N. Flynn -- Vice President, Head of Investor
Solid pipeline makes ImmunoGen (IMGN) a good long-term investment
ImmunoGen Inc. (NASDAQ: IMGN) last week reported a profit after incurring losses in the first three quarters of last year. The surprise
ImmunoGen Inc. (IMGN) Q4 2020 Earnings Call Transcript
ImmunoGen Inc. (NASDAQ: IMGN) Q4 2020 earnings call dated Feb. 12, 2021 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor
Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ: CORT) Q4 2020 earnings call dated Feb. 08, 2021 Corporate Participants: Charles Robb -- Chief Financial Officer Joseph K. Belanoff -- Chief
Eylea recovery, COVID antibody cocktail make Regeneron an attractive bet
After last year's mixed performance, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) looks to take advantage of the robust pipeline and the success of
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2020 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Q4 2020 earnings call dated Feb. 05, 2021 Corporate Participants: Justin Holko — Vice President, Investor Relations Leonard S.
Bristol Myers (BMY) stock gains after Q4 results beat Street view
Bristol-Myers Squibb Company (NYSE: BMY) Thursday reported stronger-than-expected fourth-quarter results. The company's stock gained in the pre-market session soon after the announcement.
Biogen, Inc. (BIIB) Q4 2020 Earnings Call Transcript
Biogen, Inc. (NASDAQ: BIIB) Q4 2020 earnings call dated Feb. 03, 2021 Corporate Participants: Mike Hencke -- Director, Investor Relations Michel Vounatsos -- Chief Executive Officer
Infographic: Key financials of Biogen (BIIB) Q4 2020 earnings report
Biogen (NASDAQ: BIIB) reported fourth-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 22% decline in
Vertex Pharmaceuticals Inc (VRTX) Q4 2020 Earnings Call Transcript
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q4 2020 earnings call dated Feb. 01, 2021 Corporate Participants: Michael Partridge -- Senior Vice President of Investor Relations
Novavax (NVAX) brings its share to the COVID-19 vaccine table; stock soars
Novavax Inc.’s (NASDAQ: NVAX) shares soared 50% in morning hours on Friday after the company announced that its COVID-19 vaccine candidate displayed
Fate Therapeutics (FATE) looks headed for a turnaround post-COVID
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharma company, has been drawing the market's attention after reporting positive results from advanced-stage clinical
Codexis (CDXS) may be moving closer to profitability, after beating slowdown
Biosciences company Codexis, Inc. (NASDAQ: CDXS) has emerged stronger from a rough patch, supported mainly by the resilience of its partners to
Covid vaccine won’t dent Ampio Pharma’s market: CEO Michael Macaluso
Since its foundation in 2008, Ampio Pharmaceuticals (NYSE: AMPE) has been focused on delivering a drug that treats inflammation caused by a
Moderna (MRNA): Development programs, additional approvals provide optimism
Moderna Inc. (NASDAQ: MRNA) seems to be on a roll right now. The stock has skyrocketed over 500% in the past one
Moderna’s (MRNA) stock gains on COVID-19 vaccine approval from the European Commission
Shares of Moderna Inc. (NASDAQ: MRNA) gained 6.3% in afternoon hours on Wednesday as the company received approval from the European Commission
Eli Lilly (LLY) is paving the way to a strong 2021
Shares of Eli Lilly & Co. (NYSE: LLY) were up over 2% on Wednesday. The stock has gained over 30% since the